Literature DB >> 26545376

Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study.

André Hennigs1, Hannah Biehl2, Geraldine Rauch3, Michael Golatta2, Patrik Tabatabai2, Christoph Domschke2, Sarah Schott2, Markus Wallwiener2, Florian Schütz2, Christof Sohn2, Jörg Heil2.   

Abstract

BACKGROUND: We analyzed the change of aesthetic outcome (AO) over time and explored factors characterizing poor AO after breast-conserving surgery (BCS).
METHODS: This prospective single-center cohort study included 849 patients preoperatively planned for BCS between September 2007 and December 2011. Long-term follow-up was made once in 2013. AO was measured by the Aesthetic Status (AS) of the Breast Cancer Treatment Outcome Scale questionnaire. Clinical, surgical, and pathologic variables were evaluated to identify predictors of poor AO. We applied single factor variance analyses and univariable logistic regression analyses for outcome analysis.
RESULTS: The long-term follow-up rate in 2013 was 73 % (621 nonrecurrent with final BCS). A poor or fair AO was reported in 30 (4.8 %) and 98 (15.8 %) of these 621 patients, respectively. Single factor variance analysis showed a negative impact of higher specimen weight on AO (p < 0.001). Univariable logistic regression analysis revealed the following risk factors for poor AO: radial breast incision [odds ratio (OR) 1.97], periareolar incision (OR 1.85), fishmouth-shaped incision with resection of the nipple-areola complex (OR 8.12), impaired wound healing (OR 3.14), and seroma (OR 2.16). No patient rating her AO as fair or poor shortly after BCS improved in the long-term follow-up.
CONCLUSIONS: The incidence of poor AO is relatively rare but increases in the long-term follow-up. Patients experiencing poor AO after BCS are likely to remain unsatisfied with the outcome over time. Factors predicting unfavorable AO can assist preoperative planning with regards to the choice between simple breast conserving techniques or more complex oncoplastic procedures.

Entities:  

Mesh:

Year:  2015        PMID: 26545376     DOI: 10.1245/s10434-015-4943-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Failed Breast Conservation Therapy Predicts Higher Frequency of Revision Surgery following Mastectomy with Reconstruction.

Authors:  Danielle H Rochlin; Clifford C Sheckter; Arash Momeni
Journal:  Plast Reconstr Surg       Date:  2022-04-01       Impact factor: 5.169

2.  Aesthetic result after breast-conserving therapy is associated with quality of life several years after treatment. Swedish women evaluated with BCCT.core and BREAST-Q™.

Authors:  Cecilia Dahlbäck; Jenny Heiman Ullmark; Martin Rehn; Anita Ringberg; Jonas Manjer
Journal:  Breast Cancer Res Treat       Date:  2017-05-23       Impact factor: 4.872

3.  Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance.

Authors:  Lisanne L de Boer; Esther Kho; Koen K Van de Vijver; Marie-Jeanne T F D Vranken Peeters; Frederieke van Duijnhoven; Benno H W Hendriks; Henricus J C M Sterenborg; Theo J M Ruers
Journal:  Breast Cancer Res       Date:  2021-05-22       Impact factor: 6.466

4.  Effects of Breast-Conserving Surgery Combined with Immediate Autologous Fat Grafting on Oncologic Safety, Satisfaction and Psychology in Patients with Breast Cancer: A Retrospective Cohort Study.

Authors:  Fang-Xue Gong; Xin Zhou; Zhao-He Niu; Yan Mao; Yong-Mei Wang; Meng Lv; Xue-Qiang Gao; Wen-Jing Liu; Hai-Bo Wang
Journal:  Cancer Manag Res       Date:  2022-03-10       Impact factor: 3.989

5.  Long-Term Patient Satisfaction and Quality of Life After Breast-Conserving Therapy: A Prospective Study Using the BREAST-Q.

Authors:  Ilona Stolpner; Jörg Heil; Fabian Riedel; Markus Wallwiener; Benedikt Schäfgen; Manuel Feißt; Michael Golatta; André Hennigs
Journal:  Ann Surg Oncol       Date:  2021-07-19       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.